Celsion Corporation Stock Nasdaq
Stocks
US15117N3052
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 09-24 | IMUNON, Inc. Presents Update On IMNN-001 Development Program For Women With Newly Diagnosed Advanced Ovarian Cancer | CI |
| 09-23 | Imunon, Inc. - Shareholder/Analyst Call |
| Market Cap | 5.64M 5.02M 4.65M 4.22M 7.92M 534M 8.06M 55.82M 21.93M 280M 21.15M 20.71M 892M | P/E 2026 * |
-0.42x | P/E 2027 * | -0.54x |
|---|---|---|---|---|---|
| Enterprise Value | 5.64M 5.02M 4.65M 4.22M 7.92M 534M 8.06M 55.82M 21.93M 280M 21.15M 20.71M 892M | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
93.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celsion Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Stacy Lindborg
CEO | Chief Executive Officer | 56 | 2024-05-12 |
Joshua Blacher
DFI | Director of Finance/CFO | 53 | 2026-06-30 |
Douglas Faller
CTO | Chief Tech/Sci/R&D Officer | 73 | 2025-02-17 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Tardugno
CHM | Chairman | 75 | 2014-10-06 |
Frederick Fritz
BRD | Director/Board Member | 75 | 2011-07-07 |
Donald Braun
BRD | Director/Board Member | 76 | 2015-12-14 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.21% | -6.36% | +49.00% | +74.13% | 66.34B | |
| -0.22% | +6.53% | +11.68% | +90.35% | 52.92B | |
| +0.82% | +5.41% | +8.05% | +74.45% | 54.82B | |
| +2.56% | +4.58% | +25.31% | +49.15% | 44.09B | |
| +0.25% | +9.81% | +22.24% | +128.74% | 43.72B | |
| +0.28% | +2.71% | +271.57% | +982.84% | 42.13B | |
| +0.10% | +9.96% | +17.15% | +59.33% | 33.96B | |
| -1.30% | -3.61% | +37.37% | +7.16% | 26.17B | |
| +0.69% | +5.60% | +36.60% | +26.39% | 23.37B | |
| Average | +0.29% | +4.78% | +53.22% | +165.84% | 43.06B | |
| Weighted average by Cap. | +0.32% | +4.67% | +52.27% | +169.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -14.47M -12.88M -11.93M -10.81M -20.32M -1.37B -20.67M -143M -56.26M -717M -54.27M -53.14M -2.29B | -18.55M -16.51M -15.3M -13.87M -26.06M -1.76B -26.5M -184M -72.14M -920M -69.59M -68.15M -2.93B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
